Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Ahmann, 2008, Effect of tissue shipping on plasma cell isolation, viability, and RNA integrity in the context of a centralized good laboratory practice-certified tissue banking facility, Cancer Epidemiol. Biomarkers Prev., 17, 666, 10.1158/1055-9965.EPI-07-2649 Andrulis, 2013, Targeting the BRAF V600E mutation in multiple myeloma, Cancer Discov., 3, 862, 10.1158/2159-8290.CD-13-0014 Annunziata, 2007, Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma, Cancer Cell, 12, 115, 10.1016/j.ccr.2007.07.004 Annunziata, 2011, A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression, Blood, 117, 2396, 10.1182/blood-2010-04-278788 Beroukhim, 2007, Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma, Proc. Natl. Acad. Sci. USA, 104, 20007, 10.1073/pnas.0710052104 Campbell, 2010, The patterns and dynamics of genomic instability in metastatic pancreatic cancer, Nature, 467, 1109, 10.1038/nature09460 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 Carter, 2012, Absolute quantification of somatic DNA alterations in human cancer, Nat. Biotechnol., 30, 413, 10.1038/nbt.2203 Chapman, 2011, Initial genome sequencing and analysis of multiple myeloma, Nature, 471, 467, 10.1038/nature09837 Chen, 2010, Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma, Blood, 115, 61, 10.1182/blood-2009-03-210526 Cirstea, 2013, Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs, Leukemia, 27, 2366, 10.1038/leu.2013.194 Comino-Méndez, 2011, Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma, Nat. Genet., 43, 663, 10.1038/ng.861 D’Costa, 2009, Blimp1 is limiting for transformation in a mouse plasmacytoma model, Blood, 113, 5911, 10.1182/blood-2008-08-172866 Dahlman, 2012, BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors, Cancer Discov., 2, 791, 10.1158/2159-8290.CD-12-0097 Demchenko, 2010, Classical and/or alternative NF-kappaB pathway activation in multiple myeloma, Blood, 115, 3541, 10.1182/blood-2009-09-243535 Di Bernardo, 2008, A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia, Nat. Genet., 40, 1204, 10.1038/ng.219 Ding, 2012, Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing, Nature, 481, 506, 10.1038/nature10738 Egan, 2012, Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides, Blood, 120, 1060, 10.1182/blood-2012-01-405977 Fisher, 2011, A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries, Genome Biol., 12, R1, 10.1186/gb-2011-12-1-r1 Flaherty, 2012, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations, N. Engl. J. Med., 367, 1694, 10.1056/NEJMoa1210093 Fonseca, 2009, International Myeloma Working Group molecular classification of multiple myeloma: spotlight review, Leukemia, 23, 2210, 10.1038/leu.2009.174 Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N. Engl. J. Med., 366, 883, 10.1056/NEJMoa1113205 Gnirke, 2009, Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing, Nat. Biotechnol., 27, 182, 10.1038/nbt.1523 Holien, 2012, Addiction to c-MYC in multiple myeloma, Blood, 120, 2450, 10.1182/blood-2011-08-371567 Jovanovic, 2010, Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations, J. Invest. Dermatol., 130, 618, 10.1038/jid.2009.287 Kamada, 2012, Identification of unbalanced genome copy number abnormalities in patients with multiple myeloma by single-nucleotide polymorphism genotyping microarray analysis, Int. J. Hematol., 96, 492, 10.1007/s12185-012-1171-1 Keats, 2007, Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma, Cancer Cell, 12, 131, 10.1016/j.ccr.2007.07.003 Keats, 2012, Clonal competition with alternating dominance in multiple myeloma, Blood, 120, 1067, 10.1182/blood-2012-01-405985 Landau, 2013, Clonal evolution in hematological malignancies and therapeutic implications, Leukemia Landau, 2013, Evolution and impact of subclonal mutations in chronic lymphocytic leukemia, Cell, 152, 714, 10.1016/j.cell.2013.01.019 Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213 Lenz, 2010, Aggressive lymphomas, N. Engl. J. Med., 362, 1417, 10.1056/NEJMra0807082 Lin, 2007, Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown, Cancer Res., 67, 11914, 10.1158/0008-5472.CAN-07-1868 Lohr, 2012, Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing, Proc. Natl. Acad. Sci. USA, 109, 3879, 10.1073/pnas.1121343109 Mahindra, 2012, Latest advances and current challenges in the treatment of multiple myeloma, Nat. Rev. Clin. Oncol., 9, 135, 10.1038/nrclinonc.2012.15 Mandelbaum, 2010, BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma, Cancer Cell, 18, 568, 10.1016/j.ccr.2010.10.030 Mermel, 2011, GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers, Genome Biol., 12, R41, 10.1186/gb-2011-12-4-r41 Morin, 2011, Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma, Nature, 476, 298, 10.1038/nature10351 Nik-Zainal, 2012, The life history of 21 breast cancers, Cell, 149, 994, 10.1016/j.cell.2012.04.023 Palumbo, 2011, Multiple myeloma, N. Engl. J. Med., 364, 1046, 10.1056/NEJMra1011442 Pasqualucci, 2001, Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas, Nature, 412, 341, 10.1038/35085588 Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 Salhia, 2010, DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors, Cancer Res., 70, 6934, 10.1158/0008-5472.CAN-10-0282 Shaffer, 2008, IRF4 addiction in multiple myeloma, Nature, 454, 226, 10.1038/nature07064 Shah, 2012, The clonal and mutational evolution spectrum of primary triple-negative breast cancers, Nature, 486, 395, 10.1038/nature10933 Shou, 2000, Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma, Proc. Natl. Acad. Sci. USA, 97, 228, 10.1073/pnas.97.1.228 Subramanian, 2005, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. USA, 102, 15545, 10.1073/pnas.0506580102 Tai, 2007, Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis, Blood, 110, 1656, 10.1182/blood-2007-03-081240 Walker, 2012, Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma, Blood, 120, 1077, 10.1182/blood-2012-03-412981 Walter, 2012, Clonal architecture of secondary acute myeloid leukemia, N. Engl. J. Med., 366, 1090, 10.1056/NEJMoa1106968 Wilmott, 2012, Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine, Mol. Cancer Ther., 11, 2704, 10.1158/1535-7163.MCT-12-0530